Genmab A/S (OTCMKTS:GNMSF) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened

by · The Cerbat Gem

Genmab A/S (OTCMKTS:GNMSF – Get Free Report) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $307.65 and traded as high as $319.1455. Genmab A/S shares last traded at $319.1455, with a volume of 3 shares traded.

Genmab A/S Stock Up 0.7%

The stock has a 50 day moving average of $307.25 and a 200 day moving average of $263.91. The firm has a market cap of $21.09 billion, a price-to-earnings ratio of 13.60 and a beta of 0.88.

Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $6.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.86 by $1.60. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Recommended Stories